Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
This is an **oral combination drug** used for the temporary relief of symptoms caused by allergies, hay fever, or the common cold, such as runny/stuffy nose, sneezing, itchy/watery eyes, sinus congestion, and throat irritation[1][2][3][5][6][7]. It contains three components: - **Chlorpheniramine** is a first-generation antihistamine acting as a histamine H1 receptor antagonist, decreasing allergic symptoms[2][3][9]. - **Phenylephrine** is a sympathomimetic decongestant acting as an alpha-1 adrenergic receptor agonist, reducing nasal congestion[6]. - **Methscopolamine** is an anticholinergic that reduces secretions (such as nasal, bronchial, and GI), additionally decreasing gastric acid[7]. Primary indications are symptomatic relief for upper respiratory tract symptoms caused by allergies or colds. It does not treat infection or underlying causes and is used as supportive symptomatic therapy.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on chlorpheniramine + phenylephrine + methscopolamine.